...
首页> 外文期刊>Transplantation Proceedings >Generation of donor-specific anti-human leukocyte antigen antibodies after the transplantation of a fully matched kidney allograft and its impact on the selection of a subsequent renal regraft: A case report
【24h】

Generation of donor-specific anti-human leukocyte antigen antibodies after the transplantation of a fully matched kidney allograft and its impact on the selection of a subsequent renal regraft: A case report

机译:完全匹配的肾脏同种异体移植后供体特异性抗人白细胞抗原抗体的产生及其对后续肾移植物选择的影响:一例报告

获取原文
获取原文并翻译 | 示例
           

摘要

Detection of anti-human leukocyte antigen (HLA) antibodies and identification of their specificities represent important tasks for patients awaiting kidney allografts. Regarding patients immunized by pregnancies, transfusions, or previous transplantations of solid organs, the immunization status must be observed carefully because grafting them with HLA phenotypes recognized by their antibodies represents the main cause for hyper-acute or acute rejection episodes, often leading to transplant loss. A 10-year-old patient with end-stage renal insufficiency of HLA type A3, 25; B8, 18, (Bw6); Cw7,12; DR15,17; DR51,52; DQ2,6 received a deceased donor graft showing no HLA mismatch in 1998. It lost function after 8 years, resulting in the patient's re-entry onto the waiting list for kidney transplantation in 2006. Antibody screening detected anti-HLA-A25, A26, A34, and A66 (broad A10) antibodies using various techniques (DynaChip, Single Antigen enzyme-linked immunosorbent assay [ELISA]). Additionally, a kidney offer expressing the HLA-A25 phenotype was not acceptable for the patient due to a positive complement-dependent cytotoxicity assay (CDC)-based cross-match. The question arose whether this reactivity might be due to auto-reactive antibodies directed against the HLA-A25 phenotype. However, no auto-reactive antibodies were detectable using either the CDC-based or the antibody monitoring system-ELISA-based cross-match assays. Consequently the patient was re-examined at high resolution showing the rare HLA-A*25:14 genotype. This case showed that rare alleles may result in allele-specific antibodies directed against the common variants, thus leading to unexpected positive cross-match results against apparently matched allografts.
机译:抗人白细胞抗原(HLA)抗体的检测和其特异性的鉴定是等待肾脏同种异体移植的患者的重要任务。对于通过妊娠,输血或先前的实体器官移植免疫的患者,必须仔细观察其免疫状态,因为将它们移植有抗体识别的HLA表型代表了超急性或急性排斥反应的主要原因,通常会导致移植失败。一名患有终末期肾功能不全的A3型HLA的10岁患者,年龄25; B8、18(Bw6); Cw7,12; DR15,17; DR51,52; DQ2,6于1998年收到了已故的供体移植物,显示没有HLA错配。8年后功能丧失,导致该患者于2006年重新进入等候肾脏移植的名单。抗体筛查发现抗HLA-A25,A26, A34和A66(广泛的A10)抗体使用多种技术(DynaChip,单抗原酶联免疫吸附测定[ELISA])。另外,由于基于阳性补体依赖性细胞毒性测定(CDC)的交叉匹配,表达HLA-A25表型的肾脏供体对于患者是不可接受的。产生该反应是否可能是由于针对HLA-A25表型的自身反应抗体引起的问题。但是,使用基于CDC的或基于抗体监测系统-ELISA的交叉匹配分析都无法检测到自身反应性抗体。因此,患者被高分辨率再次检查,显示罕见的HLA-A * 25:14基因型。这种情况表明,罕见的等位基因可能会导致针对共同变异体的等位基因特异性抗体,从而导致针对明显匹配的同种异体移植物产生意想不到的阳性交叉匹配结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号